CANDIDA

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece

Retrieved on: 
Monday, October 16, 2023

JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023.

Key Points: 
  • JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023.
  • Title: SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against Broad-spectrum of Fungal Pathogens, and Dose-Dependent Tissue Distribution In Vivo
    Time: 3:35 p.m EEST / 8:35 a.m. EDT

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Retrieved on: 
Wednesday, August 30, 2023

Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market

Key Points: 
  • Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market
    WASHINGTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced the journal, New Microbes and New Infections , has published non-clinical study results showing tafenoquine exhibits broad spectrum antifungal activity, including against Candida spp.
  • in cell culture, and decreases fungal burden in the lungs in an invasive pulmonary model of Rhizopus in mice.
  • 60P was recently awarded a U.S. patent covering tafenoquine for treatment of COVID-19 and other lung infections.
  • “A substantial unmet need exists for clinical therapies that treat and prevent life-threatening fungal infections,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow.

Lundquist Principal Investigator Dr. Michael Yeaman Awarded $11.5 Million NIAID/HHS Grant for Innovative Research To Understand and Solve Persistent Bloodstream Infections

Retrieved on: 
Tuesday, August 15, 2023

In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.

Key Points: 
  • In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.
  • The focus of this U19 is on infections caused by the bacterium Staphylococcus, including methicillin-resistant S. aureus (MRSA) and the invasive fungus, Candida.
  • Dr. Yeaman and team made previous discoveries that laid essential groundwork for this project to find new ways to prevent and treat persistent bloodstream infections.
  • “We will use state-of-the-art technologies in synergistic research to understand human-pathogen interactions driving persistence,” said Dr. Yeaman.

New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu

Retrieved on: 
Thursday, July 27, 2023

REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS) today announced new data supporting the development of its planned CT/NG/TV and vaginal infection panels. Results from these studies, presented in poster sessions at the 2023 IDSOG Annual Meeting in Denver, Colorado, support Talis Biomedical’s mission to advance health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.

Key Points: 
  • “The COVID-19 pandemic accelerated the development of numerous molecular point-of-care platforms to bring rapid respiratory testing closer to patients.
  • Unfortunately, very few are designed to effectively address the needs of women’s and sexual health,” said Rob Kelley, chief executive officer at Talis Biomedical.
  • In females, CT and TV were detected in 19/20 contrived vaginal swab samples at concentrations of 1 IFU/mL and 5 cells/mL, respectively.
  • LODs will be confirmed once a fully developed vulvovaginal candidiasis assay is integrated on the Talis One test cartridge.

Global Invasive Fungal Infections Market Report 2023: Increasing Invasive Fungal Infections with Life-threatening Conditions Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, May 29, 2023

However, there are also antibody molecules in early preclinical development, which are currently not on the market.

Key Points: 
  • However, there are also antibody molecules in early preclinical development, which are currently not on the market.
  • The increasing use of broad-spectrum antibiotics, the aging population, and the growing prevalence of immunocompromised patients are driving the growth of invasive candidiasis.
  • By Region: The report provides insight into the invasive fungal infections market based on the geographical operations, namely North America, Europe, Asia Pacific, and ROW.
  • The North American region has emerged as a dominant player in the invasive fungal infections market, owing to several key factors.

How do _Candida auris_ and other fungi develop drug resistance? A microbiologist explains

Retrieved on: 
Wednesday, May 3, 2023

You might have to take a combination of drugs for weeks to overcome the infection, which could result in more severe side effects.

Key Points: 
  • You might have to take a combination of drugs for weeks to overcome the infection, which could result in more severe side effects.
  • The yeast Candida auris has recently emerged as a potentially dangerous fungal infection for hospital patients and nursing home residents.
  • I am a microbiologist researching new ways to kill fungi.

Targeting the sensitive parts of fungal cells

    • Fungal cells contain a structure called a cell wall that helps maintain their shape and protects them from the environment.
    • Fungal cell walls are constructed in part from several different types of polysaccharides, which are long strings of sugar molecules linked together.
    • The fungal cell wall is an attractive target for drugs because human cells do not have a cell wall, so drugs that block chitin and beta-glucan production will have fewer side effects.

How fungi become drug resistant

    • For decades, scientists have been studying how fungi overcome drugs designed to weaken or kill them.
    • In the case of echinocandins, Candida auris commonly uses three tricks to beat these treatments: hide, build and change.
    • The third trick fungi rely on is to change the shape of the beta-glucan production enzyme so echinocandins cannot block it.
    • These mutations allow beta-glucan production to continue even in the presence of the drug.

New tactics to fight fungi

    • Thankfully, scientists and physicians are researching new ways to kill Candida auris and similar fungi.
    • For example, there are two drugs in development, rezafungin and ibrexafungerp, that appear to be able to stop beta-glucan production even in fungi resistant to echinocandins.
    • A complementary approach my research group is exploring is whether a class of enzymes called glycoside hydrolases might also be able to combat drug-resistant fungi.

Eden Park Introduces TrofferShield222 Continuous Disinfection to Create Safe and Healthy Indoor Commercial Spaces

Retrieved on: 
Tuesday, April 25, 2023

Eden Park, an industry-leading manufacturer of Far-UVC technology for continuous disinfection of air and surfaces, is excited to introduce TrofferShield222, the first dual-purpose recessed lighting solution dedicated to continuous disinfection of well-populated commercial spaces.

Key Points: 
  • Eden Park, an industry-leading manufacturer of Far-UVC technology for continuous disinfection of air and surfaces, is excited to introduce TrofferShield222, the first dual-purpose recessed lighting solution dedicated to continuous disinfection of well-populated commercial spaces.
  • TrofferShield222 features thin-panel Far-UVC technology integrated into standard LED “troffer” lighting fixtures that fit seamlessly into most 2’x2’ and 2’x4’ tiled drop ceilings.
  • Each TrofferShield222 fixture provides safe and effective continuous disinfection for a 10’x10’ space with ceilings up to 12’ in height.
  • The built-in LED lighting is designed for adjustable CCT (3500 K, 4000 K, 5000 K).

Eden Park Introduces BusShield222, the First Germicidal Far-UVC Solution Dedicated to Continuous Disinfection of School Buses

Retrieved on: 
Tuesday, April 18, 2023

Eden Park, an industry-leading manufacturer of Far-UVC technology for continuous disinfection of air and surfaces, is excited to introduce BusShield222™, the first solution dedicated to continuous disinfection of school bus and public transportation fleets.

Key Points: 
  • Eden Park, an industry-leading manufacturer of Far-UVC technology for continuous disinfection of air and surfaces, is excited to introduce BusShield222™, the first solution dedicated to continuous disinfection of school bus and public transportation fleets.
  • View the full release here: https://www.businesswire.com/news/home/20230418005461/en/
    Parents need to feel safe when putting their children on buses.
  • BusShield222 provides safe and effective school bus disinfection for students, parents, staff, and drivers.
  • “One thing the COVID-19 pandemic has shown is that school buses can be a high-risk area for transmission of viruses and bacteria,” said Eden Park CEO, John Yerger.

Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission

Retrieved on: 
Thursday, February 23, 2023

The Company’s Chief Executive Officer and other financial stakeholders in BeaMed recently returned from a visit to Israel to see the StingRay System first-hand.

Key Points: 
  • The Company’s Chief Executive Officer and other financial stakeholders in BeaMed recently returned from a visit to Israel to see the StingRay System first-hand.
  • The StingRay System is a novel laser-based thermal ablation technology designed for treatment of previously inoperable cases of epilepsy, and for improvement of outcomes and minimally invasive surgical options for brain tumors.
  • The first-in-class system is a comprehensive design, with planned robust safety features to constantly monitor thermal energy to minimize risk to healthy tissue.
  • BeaMed aims to offer new hope for this core group of patients, in addition to providing better surgical options for brain tumors.

Invasive Aspergillosis Drug Pipeline Report 2022: Comprehensive Insights on Active Companies and Pipeline Drugs Featuring F2G, SCYNEXIS, Pulmocide, & TFF Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022

This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.
  • The assessment part of the report embraces, in depth Invasive Aspergillosis commercial assessment and clinical assessment of the pipeline products under development.
  • This segment of the Invasive Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Invasive Aspergillosis R&D.